Michael J Detke

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies
    Jean Endicott
    New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
    J Clin Psychiatry 68:518-24. 2007
  2. ncbi Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 14:457-70. 2004
  3. ncbi Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:308-15. 2002
  4. ncbi Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    J Psychiatr Res 36:383-90. 2002
  5. ncbi Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)
    Craig H Mallinckrodt
    Lilly Research Laboratories, Indianapolis, Ind 46285, USA
    Neuropsychobiology 56:73-85. 2007
  6. ncbi Duloxetine vs. placebo in patients with painful diabetic neuropathy
    David J Goldstein
    PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Pain 116:109-18. 2005
  7. ncbi Simple options for improving signal detection in antidepressant clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Psychopharmacol Bull 40:101-14. 2007
  8. doi Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
  9. pmc The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Psychiatry 4:26. 2004
  10. ncbi Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
    David J Goldstein
    PRN Consulting, Indianapolis, IN, USA
    J Clin Psychopharmacol 24:389-99. 2004

Detail Information

Publications41

  1. ncbi Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies
    Jean Endicott
    New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
    J Clin Psychiatry 68:518-24. 2007
    ..The present work examined the efficacy of duloxetine treatment for improving functional outcomes for patients with GAD in 3 independent clinical studies...
  2. ncbi Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 14:457-70. 2004
    ..This placebo-controlled study assesses the safety and efficacy of duloxetine (80 or 120 mg/day) and paroxetine (20 mg QD) during an initial 8-week acute phase and subsequent 6-month continuation phase treatment of MDD...
  3. ncbi Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:308-15. 2002
    ..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated physical symptoms...
  4. ncbi Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    J Psychiatr Res 36:383-90. 2002
    ..There was no significant incidence of hypertension, nor any other safety issues. Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD...
  5. ncbi Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)
    Craig H Mallinckrodt
    Lilly Research Laboratories, Indianapolis, Ind 46285, USA
    Neuropsychobiology 56:73-85. 2007
    ....
  6. ncbi Duloxetine vs. placebo in patients with painful diabetic neuropathy
    David J Goldstein
    PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Pain 116:109-18. 2005
    ..Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain...
  7. ncbi Simple options for improving signal detection in antidepressant clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Psychopharmacol Bull 40:101-14. 2007
    ..Researchers may be able to take advantage of these easy-to-implement methods while we wait for further improvements in other areas...
  8. doi Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
    ..This was a randomized, double-blind, placebo-controlled clinical trial...
  9. pmc The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Psychiatry 4:26. 2004
    ..We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy...
  10. ncbi Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
    David J Goldstein
    PRN Consulting, Indianapolis, IN, USA
    J Clin Psychopharmacol 24:389-99. 2004
    ..Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder...
  11. ncbi Effects of duloxetine on painful physical symptoms associated with depression
    David J Goldstein
    Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
    Psychosomatics 45:17-28. 2004
    ..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression...
  12. doi Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Vladimir Skljarevski
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Diabetes Metab Res Rev 25:623-31. 2009
    ..To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP)...
  13. ncbi The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Pharm Des 11:1475-93. 2005
    ..More importantly, duloxetine appears to have better response rates and remission from depressive symptoms, perhaps due to its ability to treat a wider range of symptoms...
  14. ncbi Use of effect size to determine optimal dose of duloxetine in major depressive disorder
    Yili L Pritchett
    Eli Lilly and Company, Lilly Corporate Center, DC 6112, Indianapolis, IN 46285, USA
    J Psychiatr Res 41:311-8. 2007
    ..In addition, duloxetine-treated patients have significantly higher remission and response rates compared with placebo. The objective of this analysis is to determine the optimal dose of duloxetine in MDD...
  15. ncbi A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant
    Craig Mallinckrodt
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharm Stat 6:9-22. 2007
    ..Our case study suggests that the DBLE design can provide definitive answers to important questions and may be a useful design for assessing long-term treatment effects...
  16. doi Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials
    Beth A Pangallo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2643-51. 2010
    ....
  17. ncbi Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study
    David G Perahia
    Lilly Research Centre, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    Br J Psychiatry 188:346-53. 2006
    ..Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission...
  18. ncbi Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial
    David G S Perahia
    Lilly Research Centre, Erl Wood, Windlesham, Surrey, UK
    J Clin Psychiatry 70:706-16. 2009
    ..To assess the efficacy of duloxetine 60-120 mg once daily in the prevention of depressive recurrence in outpatients with recurrent major depressive disorder (MDD)...
  19. ncbi Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment schedule
    Craig H Mallinckrodt
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Stat Med 25:2384-97. 2006
    ..The present study assessed the feasibility of comparing onset of action between treatments using a categorical repeated measures approach with a traditional assessment schedule...
  20. pmc A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Int J Gen Med 1:91-102. 2009
    ..Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment...
  21. doi Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects
    Jill C Chappell
    From Eli Lilly and Company, Indianapolis, IN Institute of Clinical Chemistry and Laboratory Medicine Department of Medicine, University of Dresden, Dresden, Germany Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA MMS Holdings, Inc, Canton, MI Eli Lilly and Company, Windlesham, Surrey, UK Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL Detke Biopharma Consulting, LLC and Indiana University School of Medicine, Indianapolis, IN
    J Clin Psychopharmacol 34:9-16. 2014
    ....
  22. pmc Duloxetine in the treatment of major depressive disorder: an open-label study
    James I Hudson
    McLean Hospital, Belmont, MA, USA
    BMC Psychiatry 7:43. 2007
    ..In this study, the safety and efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined...
  23. ncbi Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 27:672-6. 2007
    ....
  24. ncbi The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Maurizio Fava
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 65:521-30. 2004
    ..It was hypothesized that resolution of both psychological and physical symptoms of depression would predict a higher percentage of patients achieving remission...
  25. ncbi Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Int Clin Psychopharmacol 22:348-55. 2007
    ....
  26. doi Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial
    I Jon Russell
    University of Texas Health Science Center, San Antonio, TX, USA
    Pain 136:432-44. 2008
    ..Study results demonstrated that duloxetine at doses of 60 mg/day and 120 mg/day appears to be safe and efficacious in patients with fibromyalgia...
  27. doi Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
    Madhukar H Trivedi
    Mood Disorders Program and Clinic, University of Texas Southwestern Medical School, Dallas, TX 75235 9119, USA
    Int Clin Psychopharmacol 23:161-9. 2008
    ..In summary, the data presented in this report provide clinical evidence of a mechanism for duloxetine involving both 5-HT and NE reuptake inhibition in humans and are consistent with preclinical evidence for 5-HT/NE reuptake inhibition...
  28. ncbi Duloxetine in treatment of anxiety symptoms associated with depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
    Depress Anxiety 18:53-61. 2003
    ..Efficacy in these three key symptom domains may in turn explain the high probabilities of remission (43-57%) observed in these studies...
  29. ncbi A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
    Lesley M Arnold
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
    Arthritis Rheum 50:2974-84. 2004
    ..To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder...
  30. ncbi Duloxetine for the treatment of major depressive disorder in older patients
    J Craig Nelson
    Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA
    Am J Geriatr Psychiatry 13:227-35. 2005
    ..The efficacy and safety of duloxetine, a dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE), were evaluated in the treatment of major depressive disorder (MDD) and associated pain symptoms in patients age 55 and older...
  31. ncbi Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder
    Pedro L Delgado
    Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA
    J Clin Psychiatry 66:686-92. 2005
    ..Post hoc analyses of pooled data from placebo-controlled studies were utilized to assess sexual functioning in patients receiving duloxetine or paroxetine...
  32. ncbi Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
    J Affect Disord 87:115-9. 2005
    ..This study investigated the rate of hypomania, mania, and hypomanic-like symptoms observed during treatment with duloxetine in patients with major depression...
  33. ncbi Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years
    Vivien K Burt
    Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Psychosomatics 46:345-54. 2005
    ..Duloxetine (60 mg/day) was demonstrated to be an effective treatment for major depressive disorder in this cohort of women ages 40-55 years...
  34. ncbi Time course of depression-symptom improvement during treatment with duloxetine
    Robert M A Hirschfeld
    University of Texas Medical Branch, Galveston, TX 77555 0188, USA
    Depress Anxiety 21:170-7. 2005
    ..These results may help clinicians establish more accurate expectations regarding treatment with duloxetine...
  35. ncbi Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies
    Stephen K Brannan
    Cyberonics, Houston, TX, USA
    J Psychiatr Res 39:161-72. 2005
    ..Thus, time to onset of effect is an important attribute of a new pharmacotherapy. We assessed the onset of effect for duloxetine, utilizing analytical methods previously recommended in the literature...
  36. ncbi Management of depression relapse: re-initiation of duloxetine treatment or dose increase
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, ACC 812, Boston, MA 02114, United States
    J Psychiatr Res 40:328-36. 2006
    ..Patients relapsing on duloxetine 60 mg QD benefited from an increase to 60 mg BID. These duloxetine doses were well tolerated and effective, and appear appropriate for MDD patients requiring treatment of relapse...
  37. ncbi Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial
    Moira Rynn
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Depress Anxiety 25:182-9. 2008
    ..Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD...
  38. ncbi The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition
    Stephane Chalon
    Neuropsychopharmacology 26:698-9; author reply 700-1. 2002
  39. ncbi Is PTSD caused by traumatic stress?
    J Alexander Bodkin
    Clinical Psychopharmacology Research Program, McLean Hospital, Belmont, MA 02478, USA
    J Anxiety Disord 21:176-82. 2007
    ..This equivalence suggests that in a treatment-seeking population, caution should be exercised in attributing the PTSD syndrome to trauma...
  40. ncbi Antidepressant-like effects of cytidine in the forced swim test in rats
    William A Carlezon
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02478, USA
    Biol Psychiatry 51:882-9. 2002
    ..Because antidepressants can reduce cocaine craving, we explored in rats the possibility that citicoline has antidepressant effects. We also tested the primary metabolites of citicoline, cytidine and choline...
  41. ncbi Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
    J Clin Psychopharmacol 25:132-40. 2005
    ..The cardiovascular effects of duloxetine appear to be comparable with medications considered to be first-line options for depression...